Welcome to the Hope Bio Blog

HOUSTON, TX, April 06, 2020 – Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19. MSCs are well-known for their immunomodulatory and regenerative potential. In a recent Phase

Partnering with Altoida, Inc. to Leverage Predictive Digital Biomarkers for Detection of Mild Cognitive Impairment due to Alzheimer’s Disease Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase I/II clinical trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Alzheimer’s Disease

Joined by University of Texas Health Science Center in Recruiting Participants HOUSTON, TX, October 16, 2019 – Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic diseases, today announced that enrollment is now open for a Phase I/II trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Traumatic Brain Injury and Hypoxic-Ischemic Ence